Product Information
LEVO-T 300 MCG TABLET is a generic product labeled by Neolpharma, Inc., priced at $0.1043 per EA under NDC 55466011511. Its NADAC has been published 531 times since Aug 3, 2016.
FDA first approved this application on Mar 1, 2002. Its Orange Book therapeutic-equivalence code is AB1,AB2,AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 ug/1
Manufacturer
Neolpharma, Inc.NDC
55466011511
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOTHYROXINE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021342FDA Approved
3/1/2002
TE Code
AB1,AB2,AB3
On Market Since
10/29/2015
Pharmacological Classes
Price Statistics
The NADAC for LEVO-T 300 MCG TABLET has been published 531 times since Aug 3, 2016, and over the history we have for it it has declined 86.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1043 per EA |
|---|---|
| All-time high | $0.8465 (Oct 12, 2016) |
| All-time low | $0.0715 (Jul 17, 2024) |
| 52-week high | $0.1234 |
| 52-week low | $0.0999 |
| Median price | $0.4521 |
| Average price | $0.4180 |
| Largest weekly change | +78.9% (Aug 21, 2024) |
| Weeks tracked | 531 |
| Tracking since | Aug 3, 2016 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Neolpharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levothyroxine Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
l-Thyroxine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVO-T 300 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVO-T 300 MCG TABLET, manufactured by Neolpharma, Inc., is $0.1043 per EA (NDC 55466011511), effective Sep 30, 2026.
How has the price of LEVO-T 300 MCG TABLET changed over time?
Over the history we have for it, the NADAC for LEVO-T 300 MCG TABLET has declined 86.5%. It has been tracked across 531 weekly CMS publications since Aug 3, 2016.
What are the highest and lowest recorded NADAC prices for LEVO-T 300 MCG TABLET?
Since Aug 3, 2016, the NADAC for LEVO-T 300 MCG TABLET has ranged from a low of $0.0715 (Jul 17, 2024) to a high of $0.8465 (Oct 12, 2016), with a median of $0.4521 per EA.
Are there cheaper alternatives to LEVO-T 300 MCG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LEVO-T 300 MCG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LEVO-T 300 MCG TABLET?
LEVO-T 300 MCG TABLET (NDC 55466011511) is labeled by Neolpharma, Inc., and CMS classifies it as a generic product.